Skip to main content

Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.

Publication ,  Journal Article
Pisetsky, DS
Published in: North Carolina medical journal
September 2017

Rheumatoid arthritis is the most common form of inflammatory arthritis. Because of advances in therapy, clinical outcomes have improved dramatically and remission is possible for many patients. These advances have come with many challenges, prompting consideration of strategies to improve diagnosis and treatment and implement more cost-effective care.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

North Carolina medical journal

DOI

ISSN

0029-2559

Publication Date

September 2017

Volume

78

Issue

5

Start / End Page

337 / 340

Related Subject Headings

  • Humans
  • Cost-Benefit Analysis
  • Biosimilar Pharmaceuticals
  • Arthritis, Rheumatoid
  • Antirheumatic Agents
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pisetsky, D. S. (2017). Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. North Carolina Medical Journal, 78(5), 337–340. https://doi.org/10.18043/ncm.78.5.337
Pisetsky, David S. “Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.North Carolina Medical Journal 78, no. 5 (September 2017): 337–40. https://doi.org/10.18043/ncm.78.5.337.
Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. North Carolina medical journal. 2017 Sep;78(5):337–40.
Pisetsky, David S. “Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges.North Carolina Medical Journal, vol. 78, no. 5, Sept. 2017, pp. 337–40. Epmc, doi:10.18043/ncm.78.5.337.
Pisetsky DS. Advances in the Treatment of Rheumatoid Arthritis: Costs and Challenges. North Carolina medical journal. 2017 Sep;78(5):337–340.

Published In

North Carolina medical journal

DOI

ISSN

0029-2559

Publication Date

September 2017

Volume

78

Issue

5

Start / End Page

337 / 340

Related Subject Headings

  • Humans
  • Cost-Benefit Analysis
  • Biosimilar Pharmaceuticals
  • Arthritis, Rheumatoid
  • Antirheumatic Agents
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 11 Medical and Health Sciences